The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published on September 26
The 100% tariff creates an unprecedented opportunity for domestic pharmaceutical manufacturers to capture market share from foreign competitors. This policy shift could drive significant revenue growth for American-based drug producers.
With imported drugs becoming prohibitively expensive, U.S. pharmaceutical companies gain a protective moat around their domestic operations. This competitive advantage could translate into sustained profitability and market dominance.
Beyond drug manufacturers, the entire American pharmaceutical ecosystem stands to benefit. Contract research organisations, distributors, and specialty suppliers could see increased demand as production shifts stateside.
The new 100% tariff on pharmaceuticals from companies without U.S. manufacturing creates a powerful competitive advantage for domestic producers. This policy shift is designed to bring critical drug production back to America, making foreign alternatives prohibitively expensive and driving demand toward U.S.-based companies.
This group includes major pharmaceutical manufacturers, supply chain partners, and contract research organisations across the American healthcare ecosystem. These companies are positioned to benefit from reduced foreign competition and increased market share as the industry reshores production to comply with new trade policies.
Each company was handpicked by professional analysts for their strong domestic manufacturing presence and ability to capitalise on this significant policy change. From established drug giants to specialised supply chain partners, these stocks represent the full spectrum of businesses poised to benefit from pharmaceutical onshoring.
Concise interpretation of the basket's market capitalization and investor implications, following FCA guidance.
PFE: $134.18B
BMY: $88.36B
LLY: $676.33B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
BHP Group recently posted a massive earnings beat driven by record copper profitability, allowing the miner to raise its dividend to a four-year high. This performance highlights a structural shift toward electrification metals, creating opportunities for industrial equipment suppliers and competing copper producers.
+6
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
14 of 16 assets in this group are rated Buy by professional analysts.
